Transition to next-gen propellants

GreenShift

We offer comprehensive support for transitioning your business to low Global Warming Potential (GWP) Hydrofluoroalkane (HFA) and Hydrofluoroolefin (HFO) propellants. OzUK boasts state-of-the-art filling facilities located at our headquarters in Chippenham, UK. These facilities enable clients to conduct innovative propellant R&D, execute product transfer studies, and conduct fundamental physicochemical and Chemistry, Manufacturing, and Controls (CMC) studies essential for Investigational New Drug (IND), Abbreviated New Drug Application (ANDA), and regulatory compliance. Our capabilities extend to filling both suspension and solution Metered Dose Inhalers (MDIs) with HFA152a and HFO1234ze, along with other cutting-edge propellants.

Why OzUK

The leadership team at OzUK brings forth a wealth of expertise in the formulation of Metered Dose Inhalers (MDIs) and the seamless transition of propellants. With a proven track record, the team has successfully developed and commercialized numerous products, particularly during the Chlorofluorocarbon (CFC) to Hydrofluoroalkane (HFA) transition. Positioned at the forefront of industry advancements, the team is well-equipped to extend its support for propellant transitions and assist in the development of next-gen MDIs.